-
Rucaparib (AG-014699): Precision Radiosensitization and D...
2025-10-22
Explore the advanced roles of Rucaparib (AG-014699, PF-01367338) as a potent PARP1 inhibitor in DNA damage response research. This article uniquely dissects its mechanism as a radiosensitizer for prostate cancer cells, highlighting DNA repair pathway modulation in PTEN-deficient and ETS gene fusion-expressing cancer models.
-
Reversine as a Precision Aurora Kinase Inhibitor: Unveili...
2025-10-21
Explore the multifaceted role of Reversine, a potent Aurora kinase inhibitor, in dissecting mitotic regulation and cell cycle checkpoints. This in-depth analysis uniquely integrates recent findings on checkpoint complex disassembly, offering advanced guidance for cancer research applications.
-
Olaparib (AZD2281): Novel Paradigms in Overcoming DNA Rep...
2025-10-20
Explore how Olaparib (AZD2281), a selective PARP-1/2 inhibitor, enables advanced cancer research by targeting DNA repair and overcoming therapy resistance in BRCA-deficient models. This article uniquely emphasizes translational strategies and mechanistic insights, differentiating from standard reviews.
-
BMN 673 (Talazoparib): PARP1/2 Inhibition at the Frontier...
2025-10-19
Explore the advanced mechanisms of BMN 673 (Talazoparib), a potent PARP1/2 inhibitor, in targeting DNA repair deficiencies and PI3K pathway modulation. This article uniquely unpacks the interplay between PARP-DNA complex trapping, homologous recombination deficiency, and therapeutic selectivity for cancer research.
-
Crizotinib Hydrochloride: Advancing ALK Kinase Inhibition...
2025-10-18
Crizotinib hydrochloride stands out as a small molecule inhibitor for cancer research, enabling high-precision inhibition of ALK, c-Met, and ROS1 kinase-driven oncogenic pathways in complex, patient-derived tumor models. Its integration into assembloid workflows is transforming experimental cancer biology, powering robust, physiologically relevant drug screening and resistance mechanism discovery.
245 records 17/17 page Previous First page 上5页 1617